RxDoctor Payments DataLook up a doctor →

Timothy McDermott, MD

Interventional Cardiology · Paducah, KYNPI 1972613487

Payments from drug & device makers

$16,993in general payments, 2019–2025

Across 453 payments — averaging $37.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Abbott$5K
  • Abiomed$3K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$832
  • E.r. Squibb & Sons, L.L.C.$493
  • Johnson & Johnson$489
  • plus $3K from 31 others

What the payments were for

  • Travel & lodging$7,13542%
  • Food & beverage$9,84958%
  • Education$90%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,993 in reported general payments places this provider in the 60th percentile of 129 interventional cardiology providers in Kentucky.

See all interventional cardiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$303,523
Medicare patients
2,546
Services billed
6,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$68,191
EntrestoSacubitril/Valsartan37$32,126
XareltoRivaroxaban16$21,250
FarxigaDapagliflozin Propanediol25$17,003
Metoprolol Succinate220$2,043
ClopidogrelClopidogrel Bisulfate118$1,056
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$699
Isosorbide Mononitrate ErIsosorbide Mononitrate78$697
Atorvastatin Calcium88$692
Nitroglycerin82$576
Amiodarone Hcl36$484
SotalolSotalol Hcl25$436
Losartan Potassium38$405
Metformin Hcl25$367
Lisinopril66$356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$353$68,19181 claims
NovartisEntresto$384$32,12637 claims
Johnson & JohnsonXarelto$489$21,25016 claims
AstraZenecaFarxiga$105$17,00325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 129 interventional cardiology providers in Kentucky.

Other interventional cardiology in Paducah

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →